Syneos Health (NASDAQ:SYNH) updated its FY 2020
After-Hours earnings guidance on Wednesday. The company provided earnings per share guidance of 3.58-3.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.59. The company issued revenue guidance of $4.88-5 billion, compared to the consensus revenue estimate of $4.94 billion.Syneos Health also updated its FY20 guidance to $3.58-3.78 EPS.
A number of brokerages have recently weighed in on SYNH. KeyCorp lifted their price objective on Syneos Health from $65.00 to $71.00 and gave the company an overweight rating in a research note on Thursday. Jefferies Financial Group lifted their price objective on Syneos Health from $62.00 to $65.00 and gave the company a buy rating in a research note on Monday, September 23rd. Robert W. Baird lifted their price objective on Syneos Health from $62.00 to $74.00 and gave the company an outperform rating in a research note on Thursday. ValuEngine raised Syneos Health from a sell rating to a hold rating in a research note on Tuesday. Finally, Citigroup began coverage on Syneos Health in a research note on Monday, January 6th. They issued a buy rating and a $75.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $63.44.
SYNH traded up $0.45 on Thursday, hitting $62.95. 12,125 shares of the company were exchanged, compared to its average volume of 407,380. Syneos Health has a twelve month low of $36.72 and a twelve month high of $64.72. The company has a market cap of $6.61 billion, a price-to-earnings ratio of 24.03, a price-to-earnings-growth ratio of 1.79 and a beta of 1.52. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 1.02. The firm has a 50-day moving average price of $57.68 and a two-hundred day moving average price of $53.16.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
See Also: What is meant by a buy rating?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.